SCHEMBL4156414

SCHEMBL4156414

Cc1ccc(N(CC[O])C(=O)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.54
PTGIR P43119 3/20 0.52
PKM P14618 1/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
TSHR P16473 1/20 0.46
CNR2 P34972 1/20 0.44
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RORC P51449 1/20 0.43
TP53 P04637 1/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
MLYCD O95822 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168860 0.88 ADRA2C (0.67) ADRA2CPTGIRALDH1A1MEN1KMT2A
SCHEMBL10794042 0.83 ALDH1A1 (0.66) ADRA2CPTGIRPKMALDH1A1MEN1
SCHEMBL11733716 0.83 ALDH1A1 (0.50) ADRA2CPTGIRPKMALDH1A1MEN1
SCHEMBL4155161 0.83 RAB9A (0.56) ADRA2CALDH1A1MEN1KMT2ANPC1
SCHEMBL1928093 0.81 PKM (0.54) ADRA2CPTGIRPKMALDH1A1MEN1
SCHEMBL4161794 0.78 ADRA2C (0.73) ADRA2CPTGIRALDH1A1MEN1KMT2A
SCHEMBL20218944 0.77 LTB4R2 (0.62) ADRA2CPKMMEN1KMT2ANPC1
SCHEMBL4163289 0.77 TSHR (0.52) ADRA2CALDH1A1MEN1KMT2ATSHR
SCHEMBL9809224 0.77 HPGD (0.66) PKMALDH1A1MEN1KMT2ATSHR
SCHEMBL9001626 0.76 ADRA2C (0.65) ADRA2CALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS LABORATORIOS SALVAT, S.A. (ES) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088438-A1 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS PPARG, PPARD, TYRO3 ADRA2C 292/4885PTGIR 845/4885PKM 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.